Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:

NCT ID: NCT02609022 Completed - Myasthenia Gravis Clinical Trials

Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Study CV-0002 is the first clinical trial administering CV-MG01 in humans. This clinical trial is a safety and proof-of-concept study (proof of mechanism of action) intended to assess the safety, tolerability and immunogenic response following 3 subcutaneous injections of CV-MG01 as a potential therapeutic vaccine / active immunotherapy in myasthenia gravis (MG) patients.

NCT ID: NCT02565576 Completed - Clinical trials for Myasthenia Gravis, Generalized

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Start date: September 29, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy of CFZ533 as an add-on therapy to standard of care in patients with moderate to severe myasthenia gravis (MG).

NCT ID: NCT02473965 Completed - Myasthenia Gravis Clinical Trials

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Start date: June 2015
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG).

NCT ID: NCT02473952 Completed - Clinical trials for Myasthenia Gravis, Generalized

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.

NCT ID: NCT02470364 Completed - Myasthenia Gravis Clinical Trials

Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F

MGQOL-15-F
Start date: June 2014
Phase: N/A
Study type: Observational

The purpose of this study is to translate and culturally adapt the MGQOL-15 (health-related quality of life scale for myasthenia gravis) for use with French-speaking patients in France and to evaluate its psychometric properties to ensure reliability and validity.

NCT ID: NCT02413580 Completed - Clinical trials for Myasthenia Gravis Exacerbations

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Start date: March 2015
Phase: Phase 3
Study type: Interventional

This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.

NCT ID: NCT02301624 Completed - Clinical trials for Refractory Generalized Myasthenia Gravis

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Start date: November 12, 2014
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).

NCT ID: NCT02118805 Completed - Stroke Clinical Trials

Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders

QUESST
Start date: October 2013
Phase:
Study type: Observational

This study is evaluating the use of two painless, non-invasive technologies in the assessment of muscle health over time in both healthy volunteers and patients who have diseases that affect the nervous system.

NCT ID: NCT02110706 Completed - Myasthenia Gravis Clinical Trials

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.

NCT ID: NCT02100969 Completed - Myasthenia Gravis Clinical Trials

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Hizentra is a safe and effective treatment for people with myasthenia gravis (MG).